Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy

Oncotarget | https://doi.org/10.18632/oncotarget.18200 Steffen Dietz, Holger Sültmann, YueJun Du, Eva Reisinger, Anja Lisa Riediger, Anna-Lena Volckmar, Albrecht Stenzinger, Matthias Schlesner, Dirk Jäger, Markus...

Bibliographic Details

Main Authors:	Dietz, Steffen (Author) , Sültmann, Holger (Author) , Du, YueJun (Author) , Riediger, Anja Lisa (Author) , Volckmar, Anna-Lena (Author) , Stenzinger, Albrecht (Author) , Schlesner, Matthias (Author) , Jäger, Dirk (Author) , Hohenfellner, Markus (Author) , Duensing, Stefan (Author) , Grüllich, Carsten (Author) , Pahernik, Sascha (Author)
Format:	Article (Journal)
Language:	English
Published:	May 23, 2017
In:	OncoTarget Year: 2017, Volume: 8, Issue: 43, Pages: 74049-74057
ISSN:	1949-2553
DOI:	10.18632/oncotarget.18200
Online Access:	Verlag, Volltext: http://dx.doi.org/10.18632/oncotarget.18200 Verlag, Volltext: http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=18200&path[]=58349
Author Notes:	Steffen Dietz, Holger Sültmann, YueJun Du, Eva Reisinger, Anja Lisa Riediger, Anna-Lena Volckmar, Albrecht Stenzinger, Matthias Schlesner, Dirk Jäger, Markus Hohenfellner, Stefan Duensing, Carsten Grüllich and Sascha Pahernik